Addex Therapeutics (XSWX:ADXN) Total Liabilities : CHF3.50 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Addex Therapeutics Total Liabilities?

Addex Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was CHF3.50 Mil.

Addex Therapeutics's quarterly Total Liabilities declined from Jun. 2023 (CHF2.87 Mil) to Sep. 2023 (CHF2.19 Mil) but then increased from Sep. 2023 (CHF2.19 Mil) to Dec. 2023 (CHF3.50 Mil).

Addex Therapeutics's annual Total Liabilities declined from Dec. 2021 (CHF5.61 Mil) to Dec. 2022 (CHF3.37 Mil) but then increased from Dec. 2022 (CHF3.37 Mil) to Dec. 2023 (CHF3.50 Mil).

Addex Therapeutics Total Liabilities Historical Data

The historical data trend for Addex Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Addex Therapeutics Total Liabilities Chart

Addex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

7.51

5.57

5.61

3.37

3.50

Addex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															3.37	3.22	2.87	2.19	3.50

Addex Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Addex Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.893	+	(0.07	+	1.6653345369377E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.089	+	0.444)
	=	3.50

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	4.642	-	1.145
	=	3.50

Addex Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.893	+	(0.07	+	1.6653345369377E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.089	+	0.444)
	=	3.50

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	4.642	-	1.145
	=	3.50

Addex Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Addex Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Addex Therapeutics (XSWX:ADXN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Addex Therapeutics Ltd (XSWX:ADXN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ADXN:USA ADXNz:UK APE1:Germany

Address

Chemin des Aulx 12, Plan-les-Ouates, P.O. Box 68, Geneva, CHE, 1202

Website

https://www.addextherapeutics.com

Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.

Addex Therapeutics (XSWX:ADXN) Headlines

From GuruFocus

Enamine Extend Collaboration With Prominent Swiss Biotech

By Business Wire Business Wire • 02-24-2021

Thinking about buying stock in Applovin, Sonos, WiMi Hologram Cloud, Addex Therapeutics, or Snap?

By PRNewswire PRNewswire • 02-09-2023